Impax Laboratories

Impax Laboratories, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and marketing generic and branded products. Impax Generics includes the company’s legacy Global Pharmaceuticals business as well as the acquired CorePharma and Lineage Therapeutics businesses. Impax Specialty Pharma includes the legacy Impax Pharmaceuticals business as well as the acquired Amedra Pharmaceuticals business. Impax’s Generics Division focuses on a broad range of therapeutic areas, including products having technically challenging drug-delivery mechanisms or unique product formulations. In addition to developing solid oral dosage products, the company’s portfolio includes alternative dosage form products, primarily through alliance and collaboration agreements with third parties. The Company’s Specialty Pharma Division is focused on the development and promotion, through the company’s specialty sales force, of proprietary branded pharmaceutical products for the treatment of Central Nervous System disorders and other select specialty segments. The Impax Specialty Pharma Division currently has one internally developed branded pharmaceutical product, RYTARY (IPX066), an extended-release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, postencephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication.

Company Growth (employees)
Type
Public
HQ
Hayward, US
Founded
1999
Size (employees)
1,495 (est)
Impax Laboratories was founded in 1999 and is headquartered in Hayward, US

Impax Laboratories Office Locations

Impax Laboratories has offices in Hayward, Philadelphia, Chalfont, Zhunan Township and in 1 other location
Hayward, US (HQ)
30831 Huntwood Ave
Zhunan Township, TW
No. 1, Ke Dong 3rd Road Jhunan Science Park Miaoli County 350
Chalfont, US
121 New Britain Blvd
Philadelphia, US
3735 Castor Ave

Impax Laboratories Data and Metrics

Impax Laboratories Financial Metrics

Impax Laboratories's revenue was reported to be $824.4 m in FY, 2016 which is a 4% decrease from the previous period.
USD

Revenue (FY, 2016)

824.4 m

Revenue growth (FY, 2015 - FY, 2016), %

(4%)

Net income (FY, 2016)

(472 m)

Market capitalization (18-Aug-2017)

1.3 b

Cash (31-Dec-2015)

340.4 m
Impax Laboratories's current market capitalization is $1.3 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

511.5 m596 m860.5 m824.4 m

Revenue growth, %

17%44%(4%)

Cost of goods sold

312.2 m283.4 m508.1 m

Gross profit

199.3 m312.7 m352.4 m

Gross profit Margin, %

39%52%41%

Operating expense total

205.7 m223.8 m282.8 m

EBIT

(6.4 m)88.8 m69.6 m

EBIT margin, %

(1%)15%8%

Interest expense

(419 k)(43 k)(27.3 m)

Interest income

1.3 m1.5 m1 m

Pre tax profit

146.9 m90.6 m59.4 m

Income tax expense

45.7 m33.2 m20.4 m

Net Income

101.3 m57.4 m39 m(472 m)
USDFY, 2013FY, 2014FY, 2015

Cash

184.6 m214.9 m340.4 m

Accounts Receivable

113 m146.5 m324.5 m

Inventories

12.7 m33.7 m31.7 m

Current Assets

659.7 m730.5 m822.1 m

PP&E

188.2 m188.2 m214.2 m

Goodwill

27.6 m27.6 m210.2 m

Total Assets

996.9 m1.1 b1.9 b

Accounts Payable

26.8 m32 m56.3 m

Current Liabilities

153.9 m158.7 m326.8 m

Additional Paid-in Capital

336.6 m364.1 m504.1 m

Retained Earnings

473.9 m531.2 m570.2 m

Total Equity

1.1 b

Financial Leverage

1.8 x
USDFY, 2013FY, 2014FY, 2015

Net Income

101.3 m57.4 m39 m

Depreciation and Amortization

36 m34 m68.6 m

Accounts Receivable

(21 m)(33 m)(120 m)

Inventories

7.1 m(24 m)(5.9 m)

Accounts Payable

4.7 m(9 m)48.1 m

Cash From Operating Activities

149.9 m32.8 m71.9 m

Purchases of PP&E

(32.8 m)(29.9 m)(25.2 m)

Cash From Investing Activities

(115.9 m)(16.6 m)(467.5 m)

Cash From Financing Activities

9 m14.4 m521.4 m

Interest Paid

89 k15.4 m

Income Taxes Paid

34.3 m43.2 m

Impax Laboratories Market Value History

Impax Laboratories Median Salaries

Source: 25 public H-1B filings from Impax Laboratories

Traffic Overview of Impax Laboratories

Impax Laboratories Company Life and Culture

You may also be interested in